JP2021508683A5 - - Google Patents

Info

Publication number
JP2021508683A5
JP2021508683A5 JP2020533728A JP2020533728A JP2021508683A5 JP 2021508683 A5 JP2021508683 A5 JP 2021508683A5 JP 2020533728 A JP2020533728 A JP 2020533728A JP 2020533728 A JP2020533728 A JP 2020533728A JP 2021508683 A5 JP2021508683 A5 JP 2021508683A5
Authority
JP
Japan
Prior art keywords
antigen
binding fragment
isolated antibody
antibody
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020533728A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021508683A (ja
JP7317016B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/066620 external-priority patent/WO2019126401A1/en
Publication of JP2021508683A publication Critical patent/JP2021508683A/ja
Publication of JP2021508683A5 publication Critical patent/JP2021508683A5/ja
Priority to JP2023116796A priority Critical patent/JP7667823B2/ja
Application granted granted Critical
Publication of JP7317016B2 publication Critical patent/JP7317016B2/ja
Priority to JP2025065638A priority patent/JP2025114580A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020533728A 2017-12-19 2018-12-19 抗lrp5/6抗体及び使用方法 Active JP7317016B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023116796A JP7667823B2 (ja) 2017-12-19 2023-07-18 抗lrp5/6抗体及び使用方法
JP2025065638A JP2025114580A (ja) 2017-12-19 2025-04-11 抗lrp5/6抗体及び使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762607879P 2017-12-19 2017-12-19
US62/607,879 2017-12-19
US201862680515P 2018-06-04 2018-06-04
US62/680,515 2018-06-04
PCT/US2018/066620 WO2019126401A1 (en) 2017-12-19 2018-12-19 Anti-lrp5/6 antibodies and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023116796A Division JP7667823B2 (ja) 2017-12-19 2023-07-18 抗lrp5/6抗体及び使用方法

Publications (3)

Publication Number Publication Date
JP2021508683A JP2021508683A (ja) 2021-03-11
JP2021508683A5 true JP2021508683A5 (enExample) 2022-02-07
JP7317016B2 JP7317016B2 (ja) 2023-07-28

Family

ID=66992884

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020533728A Active JP7317016B2 (ja) 2017-12-19 2018-12-19 抗lrp5/6抗体及び使用方法
JP2023116796A Active JP7667823B2 (ja) 2017-12-19 2023-07-18 抗lrp5/6抗体及び使用方法
JP2025065638A Pending JP2025114580A (ja) 2017-12-19 2025-04-11 抗lrp5/6抗体及び使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023116796A Active JP7667823B2 (ja) 2017-12-19 2023-07-18 抗lrp5/6抗体及び使用方法
JP2025065638A Pending JP2025114580A (ja) 2017-12-19 2025-04-11 抗lrp5/6抗体及び使用方法

Country Status (7)

Country Link
US (2) US11746150B2 (enExample)
EP (1) EP3731867A4 (enExample)
JP (3) JP7317016B2 (enExample)
CN (1) CN111699003B (enExample)
AU (1) AU2018393076B2 (enExample)
CA (1) CA3085785A1 (enExample)
WO (1) WO2019126401A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018211985B2 (en) 2017-01-26 2025-02-13 Surrozen Operating, Inc. Tissue-specific Wnt signal enhancing molecules and uses thereof
JP7418332B2 (ja) 2017-12-19 2024-01-19 スロゼン オペレーティング, インコーポレイテッド 抗フリズルド抗体及び使用方法
CN111699003B (zh) 2017-12-19 2024-05-03 瑟罗泽恩奥普瑞汀公司 抗lrp5/6抗体和使用方法
CN118271444A (zh) * 2017-12-19 2024-07-02 瑟罗泽恩奥普瑞汀公司 Wnt替代分子和其用途
JP2021530223A (ja) 2018-07-09 2021-11-11 スロゼン, インコーポレイテッド 組織特異性Wntシグナル増強分子及びその使用
CA3144499A1 (en) * 2019-07-02 2021-01-07 Surrozen Operating, Inc. Monospecific anti-frizzled antibodies and methods of use
US20230183336A1 (en) * 2019-08-14 2023-06-15 Modmab Therapeutics Inc. Antibodies that bind to lrp5 proteins and methods of use
CN118909117A (zh) * 2019-08-14 2024-11-08 安托拉诊疗公司 与lrp6蛋白结合的抗体及使用方法
WO2022104280A1 (en) 2020-11-16 2022-05-19 Surrozen Operating, Inc. Liver-specific wnt signal enhancing molecules and uses thereof
CR20240266A (es) * 2021-12-31 2024-11-11 Surrozen Operating Inc Compuesto específico de receptor wnt y método relacionado con este
WO2024092164A1 (en) * 2022-10-27 2024-05-02 California Institute Of Technology Targets for receptor-mediated control of therapeutic biodistribution and efficacy
US12215746B1 (en) 2023-08-22 2025-02-04 Nsk-Warner K.K. Ratchet type one-way clutch apparatus
WO2026044274A1 (en) * 2024-08-23 2026-02-26 Surrozen Operating, Inc. Wnt surrogate fusion molecule
WO2026044275A1 (en) * 2024-08-23 2026-02-26 Surrozen Operating, Inc. Wnt surrogate fusion molecule

Family Cites Families (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
US5675063A (en) 1995-02-28 1997-10-07 Loyola University Of Chicago Immortalized rabbit hybridoma fusion partner
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US7057017B2 (en) 1997-04-16 2006-06-06 Millennium Pharmaceuticals, Inc. Human dickkopf-related protein and nucleic acid molecules and uses therefor
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DE60129799T2 (de) 2000-03-31 2008-04-30 The General Hospital Corp., Boston Verfahren zur steigerung des haarwuchses durch wnt polypeptid
US7713526B2 (en) 2001-05-01 2010-05-11 The Regents Of The University Of California Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
US20030044409A1 (en) 2001-05-01 2003-03-06 Carson Dennis A. Immunologic compositions and methods for studying and treating cancers expressing frizzled antigens
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
US7135174B2 (en) 2002-01-07 2006-11-14 Amgen Fremont, Inc. Antibodies directed to PDGFD and uses thereof
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8093357B2 (en) 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
NZ537277A (en) * 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US8637506B2 (en) 2003-09-22 2014-01-28 Enzo Biochem, Inc. Compositions and methods for bone formation and remodeling
US9046537B2 (en) 2003-09-22 2015-06-02 Enzo Biochem, Inc. Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain
US8461155B2 (en) 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
US8367822B2 (en) 2003-09-22 2013-02-05 Enzo Therapeutics, Inc. Compositions and methods for bone formation and remodeling
WO2005032574A1 (en) 2003-10-03 2005-04-14 The Board Of Trustees Of The Leland Stanford Junior University Modulation of gastrointestinal epithelium proliferation through the wnt signaling pathway
JP2007512846A (ja) 2003-12-04 2007-05-24 ゼンコー・インコーポレイテッド 増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物
EP2168986A3 (en) 2004-02-19 2010-07-28 Genentech, Inc. CDR-repaired antibodies
JP5122278B2 (ja) 2004-05-13 2013-01-16 ユニバーシティ オブ バージニア パテント ファウンデーション 眼細胞生存の促進におけるラクリチンの使用
US8343922B2 (en) 2004-05-19 2013-01-01 Enzo Biochem, Inc. Compositions and methods for the stimulation or enhancement of bone formation and the self-renewal of cells
US9052324B2 (en) 2004-05-19 2015-06-09 Enzo Biochem, Inc. Compounds and assays for controlling Wnt activity
BRPI0514068B8 (pt) 2004-08-04 2021-05-25 Applied Molecular Evolution Inc anticorpo anti-cd20, e, composição farmacêutica
ES2414460T3 (es) 2004-08-04 2013-07-19 Amgen Inc. Anticuerpos para Dkk-1
DE102004050620A1 (de) 2004-10-13 2006-04-20 Eberhard-Karls-Universität Tübingen Monoklonaler Antikörper gegen Frizzled-Rezeptoren
US7462697B2 (en) 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
JP2008528010A (ja) 2005-01-31 2008-07-31 アブリンクス ナームローゼ フェンノートシャップ 重鎖抗体の可変ドメイン配列を作出する方法
AU2006230413B8 (en) 2005-03-31 2011-01-20 Xencor, Inc Fc variants with optimized properties
US7771937B2 (en) * 2005-05-20 2010-08-10 University Of Washington Methods for predicting late onset Alzheimer disease in an individual
EP1902318A1 (en) 2005-05-30 2008-03-26 AstraZeneca AB Methods for identifying fzd8 modulators and the use of such modulators for treating osteoarthritis
US7429487B2 (en) 2005-07-05 2008-09-30 Epitomics, Inc. Fusion partner for production of monoclonal rabbit antibodies
DE102005035568A1 (de) 2005-07-25 2007-02-01 M-Phasys Gmbh Frizzled 9 als Biomarker für Substrukturen des humanen Gehirns
KR101866623B1 (ko) 2005-11-28 2018-07-04 젠맵 에이/에스 재조합 1가 항체 및 그의 제조 방법
CA2635906A1 (en) 2006-02-07 2007-08-16 Wyeth Materials and methods for identifying agents that modulate norrin. norrin mimetics, and agents identified thereby
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
US8221751B2 (en) 2006-06-21 2012-07-17 Oncotherapy Science, Inc. Tumor-targeting monoclonal antibodies to FZD10 and uses thereof
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
ES2610474T3 (es) 2007-01-11 2017-04-27 Michael Bacher Diagnóstico y tratamiento de la enfermedad de Alzheimer y otras enfermedades neurodegenerativas causantes de demencia
US20100199362A1 (en) 2007-04-26 2010-08-05 President And Fellows Of Harvard College Wnt ligands involved in blood-brain barrier development and uses therefor
MX2010004761A (es) 2007-11-02 2010-05-19 Novartis Ag Moleculas y metodos para modular la proteina relacionada con el receptor de lipoproteina de baja densidad 6 (lrp6).
EP3211011A1 (en) 2007-11-16 2017-08-30 Nuvelo, Inc. Antibodies to lrp6
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
WO2009126304A1 (en) 2008-04-11 2009-10-15 Biogen Idec Ma Inc. Therapeutic combinations of anti-igf-1r antibodies and other compounds
WO2010016766A2 (en) 2008-08-08 2010-02-11 Koninklijke Nederlandse Akademie Van Wetenschappen Antibodies recognizing endogenous human lgr5 and/or lgr6
CN102239180B (zh) 2008-08-18 2014-12-31 辉瑞大药厂 抗ccr2抗体
AU2009291747B2 (en) 2008-09-10 2016-05-26 Genentech, Inc. Methods for inhibiting ocular angiogenesis
EP2331136B1 (en) 2008-09-26 2018-01-10 OncoMed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
GB0819449D0 (en) 2008-10-23 2008-12-03 Cambridge Display Tech Ltd Display drivers
US9221902B2 (en) 2008-11-07 2015-12-29 Fabrus, Inc. Combinatorial antibody libraries and uses thereof
US8642339B2 (en) 2009-02-03 2014-02-04 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium for epithelial stem cells and organoids comprising the stem cells
EP2412800A1 (en) 2010-07-29 2012-02-01 Koninklijke Nederlandse Akademie van Wetenschappen Liver organoid, uses thereof and culture method for obtaining them
US20100254979A1 (en) 2009-03-06 2010-10-07 Cisthera, Incorporated Humanized PAI-1 Antibodies and Uses Thereof
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
US9175070B2 (en) 2009-09-25 2015-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to HIV-1 and their use
EP2486126B1 (en) 2009-10-06 2017-12-06 SNU R & DB Foundation Method for differentiation into retinal cells from stem cells
US20130089554A1 (en) 2009-12-29 2013-04-11 Emergent Product Development Seattle, Llc RON Binding Constructs and Methods of Use Thereof
EP2524059A4 (en) 2010-01-13 2013-11-20 Caris Life Sciences Luxembourg Holdings DETECTION OF GASTROINTESTINAL DISEASES
US8859736B2 (en) 2010-02-19 2014-10-14 The Board Of Regents Of The University Of Oklahoma Monoclonal antibodies that inhibit the wnt signaling pathway and methods of production and use thereof
KR101899835B1 (ko) 2010-03-24 2018-09-19 제넨테크, 인크. 항-lrp6 항체
CN102971337B (zh) 2010-04-01 2016-09-21 昂考梅德药品有限公司 卷曲蛋白结合药剂及其应用
US20130274215A1 (en) 2010-04-08 2013-10-17 Fate Therapeutics, Inc. Pharmaceutical compositions to treat fibrosis
MX2012012927A (es) 2010-05-06 2013-05-01 Novartis Ag Composiciones y metodos de uso para anticuerpos multivalentes terapeuticos de proteina relacionada con lipoproteina de baja densidad 6 (lrp6).
SG185416A1 (en) * 2010-05-06 2012-12-28 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
CN103501799A (zh) 2011-01-28 2014-01-08 莱兰斯坦福初级大学评议会 Wnt组合物及其使用方法
GB201106395D0 (en) 2011-04-14 2011-06-01 Hubrecht Inst Compounds
UA117218C2 (uk) * 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
WO2013025446A2 (en) 2011-08-12 2013-02-21 Omeros Corporation Anti-fzd10 monoclonal antibodies and methods for their use
AU2012310328A1 (en) * 2011-09-23 2014-04-10 Technophage, Investigação E Desenvolvimento Em Biotecnologia, S.A. Anti-Tumor Necrosis Factor-alpha agents and uses thereof
ES2769786T3 (es) 2011-10-14 2020-06-29 Recordati Ag Anticuerpos y métodos para enfermedades relacionadas con la vía Wnt
US8883735B2 (en) 2011-11-04 2014-11-11 Novartis Ag Low density lipoprotein-related protein 6 (LRP6)-half life extender constructs
CN104203981A (zh) 2011-12-19 2014-12-10 合成免疫股份有限公司 双特异性抗体分子
SG10201601747XA (en) 2012-01-18 2016-04-28 Genentech Inc Anti-LRP5 Antibodies And Methods Of Use
EP2888279A1 (en) 2012-08-22 2015-07-01 Glaxo Group Limited Anti lrp6 antibodies
WO2014059068A1 (en) 2012-10-11 2014-04-17 The Trustees Of The University Of Pennsylvania Methods for the treatment and prevention of osteoporosis and bone-related disorders
EP2906596B1 (en) * 2012-10-12 2023-12-27 Arizona Board of Regents on behalf of Arizona State University Antibody based reagents that specifically recognize toxic oligomeric forms of tau
CN105073195A (zh) 2013-02-04 2015-11-18 昂科梅德制药有限公司 使用Wnt途径抑制剂进行治疗的方法及对该治疗的监测
HK1218930A1 (zh) 2013-02-08 2017-03-17 Abbvie Stemcentrx Llc 新型多特异性结构
CN105431161A (zh) 2013-02-21 2016-03-23 范安德尔研究所 Norrin突变体多肽、其制造方法和用途
US20140255403A1 (en) 2013-03-06 2014-09-11 Hadasit Medical Research Services & Development Ltd. Oral composition comprising a tnf antagonist and use thereof
JP2016512533A (ja) 2013-03-14 2016-04-28 オンコメッド ファーマシューティカルズ インコーポレイテッド Met結合剤およびその使用
US9850297B2 (en) 2013-03-15 2017-12-26 Amgen Inc. Secreted frizzle-related protein 5 (SFRP5) binding proteins
KR102215405B1 (ko) * 2013-03-15 2021-02-10 암젠 인크 인간 pac1 항체
AU2014306564B2 (en) 2013-08-14 2019-10-17 Antlera Therapeutics Inc. Antibodies against frizzled proteins and methods of use thereof
GB2518221A (en) 2013-09-16 2015-03-18 Sergej Michailovic Kiprijanov Tetravalent antigen-binding protein molecule
MX2016003617A (es) 2013-09-30 2016-07-21 Chugai Pharmaceutical Co Ltd Metodo para producir molecula de enlace al antigeno usando fago auxiliar modificado.
GB2519786A (en) 2013-10-30 2015-05-06 Sergej Michailovic Kiprijanov Multivalent antigen-binding protein molecules
US9629801B2 (en) * 2014-01-10 2017-04-25 Wisconsin Alumni Research Foundation Blood-brain barrier targeting antibodies
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card
WO2015109212A1 (en) 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
EA201790342A1 (ru) 2014-08-08 2017-07-31 ЭЛЕКТОР ЭлЭлСи Антитела к trem2 и способы их применения
CN107073042A (zh) 2014-09-03 2017-08-18 布里格海姆妇女医院公司 用于产生内耳毛细胞来治疗听力损失的组合物、系统和方法
JP6796059B2 (ja) 2014-09-12 2020-12-02 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Wntシグナリングアゴニスト分子
ES2808853T3 (es) 2014-11-20 2021-03-02 Hoffmann La Roche Cadenas ligeras comunes y procedimientos de uso
US9777052B2 (en) 2014-12-02 2017-10-03 The Board Of Regents Of The University Of Oklahoma R-spondin variants, compositions, and methods of use
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
WO2016168607A1 (en) 2015-04-15 2016-10-20 University Of Tennessee Research Foundation Compositions and methods of muc13 antibodies for cancer treatment and diagnosis
US20160312207A1 (en) 2015-04-21 2016-10-27 The Board Of Trustees Of The Leland Stanford Junior University R-spondin antagonists and methods of treating cancer associated with aberrant activation of wnt signaling
WO2016205551A2 (en) 2015-06-16 2016-12-22 The Regents Of The University Of California Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function
WO2016205566A1 (en) 2015-06-16 2016-12-22 The Regents Of The University Of California Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
CN108291197B (zh) 2015-10-21 2022-09-16 印第安纳大学研究与技术公司 生成人内耳感觉上皮和感觉神经元的方法
WO2017127933A1 (en) 2016-01-29 2017-08-03 The Governing Council Of The University Of Toronto Frizzled protein-binding agents and methods of use thereof
UA126657C2 (uk) 2016-02-03 2023-01-11 Емджен Рісерч (Мюнік) Ґмбг ОДНОЛАНЦЮГОВА КОНСТРУКЦІЯ АНТИТІЛА ДО BCMA І CD3<font face="Symbol">e</font>
JP7014724B2 (ja) 2016-02-06 2022-02-01 エピムアブ バイオセラピューティクス インコーポレイテッド タンデム型Fab免疫グロブリンおよびその使用
US20190093079A1 (en) 2016-03-02 2019-03-28 Frequency Therapeutics, Inc. Methods for controlled proliferation of stem cells / generating inner ear hair cells using gsk-3-alpha inhibitors
JP7023853B2 (ja) 2016-03-04 2022-02-22 アレクトル エルエルシー 抗trem1抗体及びその使用方法
US20170349659A1 (en) 2016-06-03 2017-12-07 The Board Of Trustees Of The Leland Stanford Junior University Wnt signaling agonist molecules
JP7617603B2 (ja) 2017-01-11 2025-01-20 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー R-スポンジン(rspo)サロゲート分子
AU2018211985B2 (en) 2017-01-26 2025-02-13 Surrozen Operating, Inc. Tissue-specific Wnt signal enhancing molecules and uses thereof
US11033636B2 (en) 2017-05-31 2021-06-15 Boehringer Ingelheim International Gmbh Polypeptides antagonizing Wnt signaling in tumor cells
CN118271444A (zh) * 2017-12-19 2024-07-02 瑟罗泽恩奥普瑞汀公司 Wnt替代分子和其用途
CN111699003B (zh) 2017-12-19 2024-05-03 瑟罗泽恩奥普瑞汀公司 抗lrp5/6抗体和使用方法
JP7418332B2 (ja) 2017-12-19 2024-01-19 スロゼン オペレーティング, インコーポレイテッド 抗フリズルド抗体及び使用方法
US20210032352A1 (en) 2018-02-14 2021-02-04 Antera Therapeutics Inc. Multivalent Binding Molecules Activating WNT Signaling and Uses Thereof
AU2019297522B2 (en) * 2018-07-05 2026-04-23 Surrozen Operating, Inc. Multi-specific Wnt surrogate molecules and uses thereof
JP2021530223A (ja) 2018-07-09 2021-11-11 スロゼン, インコーポレイテッド 組織特異性Wntシグナル増強分子及びその使用
US20220064337A1 (en) 2018-12-19 2022-03-03 Surrozen, Inc. Antigen binding formats for receptor complexes
AU2020221797A1 (en) 2019-02-11 2021-08-12 Surrozen Operating, Inc. Modulation of WNT signalling in ocular disorders
WO2020185960A1 (en) 2019-03-11 2020-09-17 Surrozen, Inc. Modulation of wnt signaling in gastrointestinal disorders
US20220175884A1 (en) 2019-04-02 2022-06-09 Surrozen Operating, Inc. Modulation of wnt signaling in auditory disorders
US11050604B2 (en) 2019-07-01 2021-06-29 Rampart Communications, Inc. Systems, methods and apparatuses for modulation-agnostic unitary braid division multiplexing signal transformation
CA3144499A1 (en) 2019-07-02 2021-01-07 Surrozen Operating, Inc. Monospecific anti-frizzled antibodies and methods of use
US20230138045A1 (en) 2020-02-24 2023-05-04 Surrozen Operating, Inc. Wnt super agonists
WO2022104280A1 (en) 2020-11-16 2022-05-19 Surrozen Operating, Inc. Liver-specific wnt signal enhancing molecules and uses thereof
JP7891006B2 (ja) 2021-03-10 2026-07-15 スロゼン オペレーティング, インコーポレイテッド 胃腸障害におけるwntシグナル伝達のモジュレーション
EP4401841A4 (en) 2021-09-14 2025-07-02 Surrozen Operating Inc MODULATION OF WNT SIGNALING IN PULMONARY DISORDERS

Similar Documents

Publication Publication Date Title
JP2021508247A5 (enExample)
JP2021529796A5 (enExample)
US8889130B2 (en) Treatment of osteoarthritis and pain
JP6353500B2 (ja) Dkk1抗体およびその使用方法
JP6744292B2 (ja) 多重特異性抗体
JP2023113950A (ja) Wntサロゲート分子及びその使用
AU2004207741B2 (en) Human IL-1 beta antagonists
US9073999B2 (en) Anti-IL-17 receptor A neutralizing antibodies
US9840554B2 (en) Antibodies against platelet-derived growth factor (PDGF)
JP2024001292A (ja) 多特異性Wnt代替分子及びその使用
CN103649118A (zh) 双特异性结合剂
JPWO2020022475A5 (enExample)
CA2558805A1 (en) Anti-myostatin antibodies
CA2981115C (en) Anti-dkk-1-anti-rankl bispecific antibody compounds
AU2023210235A1 (en) Anti-alk1 antibodies and methods of using the same
WO2026103698A1 (zh) 双功能融合蛋白及其应用
TW202544045A (zh) 抗群落刺激因子1受體抗體與jak抑制劑之組合療法
TW202612727A (zh) 馮威里氏病之治療
WO2023215697A1 (en) Multispecific binding molecules and methods of use thereof
TW202334209A (zh) 成骨不全症之治療
HK1250046B (en) Anti-dkk-1-anti-rankl bispecific antibody compounds
RU2020129339A (ru) Антитела с двойной специфичностью